Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts.
The effectiveness of therapies targeting specific pathways in breast cancer, such as the estrogen receptor or HER2, is limited because many tumors manifest resistance, either de novo or acquired, during the course of treatment. To investigate molecular mechanisms of resistance, we used two xenograft models of estrogen receptor-positive (ER+) breast cancer, one with and one without HER2 overexpression (MCF7/HER2-18 and MCF7 wt, respectively). Mice with established tumors were assigned to the following treatment groups: estrogen supplementation (E2), estrogen deprivation (ED), ED plus tamoxifen (Tam), all with or without the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (G). Another group received ED plus the antiestrogen fulvestrant (MCF7 wt only). Tumors with acquired or de novo resistance to these endocrine therapies were profiled for gene expression and compared with tumors in the E2 control group. One class of genes underexpressed in endocrine-resistant tumors (relative to E2-treated tumors) were estrogen inducible in vitro and associated with ER+ human breast cancers (luminal subtype). Another class of genes overexpressed in tumors with acquired resistance in both models represented transcriptional targets of HER2 signaling and was associated with ER-/HER2+ human cancers (ERBB2+ subtype). A third class of genes overexpressed in MCF7/HER2-18 tumors exhibiting de novo resistance to tamoxifen was associated with ER+ human cancers but not with estrogen-regulated genes. Thus, in response to various endocrine therapy regimens, these xenograft breast tumors shut down classic estrogen signaling and activate alternative pathways such as HER2 that contribute to treatment resistance. Over time, the molecular phenotype of breast cancer can change.
Creighton
Chad J
CJ
The Dan L. Duncan Cancer Center, Baylor College of Medicine, Room N1230.02, One Baylor Plaza-BCM 600, Houston, TX 77030, USA.
Massarweh
Suleiman
S
Huang
Shixia
S
Tsimelzon
Anna
A
Hilsenbeck
Susan G
SG
Osborne
C Kent
CK
Shou
Jiang
J
Malorni
Luca
L
Schiff
Rachel
R
D000818:Animals; D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism; D045744:Cell Line, Tumor; D019008:Drug Resistance, Neoplasm; D004958:Estradiol / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology; D047628:Estrogen Receptor alpha / Q000096:biosynthesis / Q000378:metabolism; D004967:Estrogens / Q000172:deficiency; D000077267:Fulvestrant; D000077156:Gefitinib; D020869:Gene Expression Profiling; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D010052:Ovariectomy; D011799:Quinazolines / Q000008:administration & dosage; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis / Q000378:metabolism; D013629:Tamoxifen / Q000008:administration & dosage / Q000494:pharmacology*; D023041:Xenograft Model Antitumor Assays
D018931:Antineoplastic Agents, Hormonal; D004958:Estradiol; D047628:Estrogen Receptor alpha; D004967:Estrogens; D000077267:Fulvestrant; D000077156:Gefitinib; D011799:Quinazolines; D012333:RNA, Messenger; D018719:Erb-b2 Receptor Tyrosine Kinases; D013629:Tamoxifen
Br J Cancer. 2004 Mar;90 Suppl 1:S2-6
15094757
Breast Cancer Res Treat. 1994 Jan;29(1):117-25
7912565
Cancer Res. 2008 Feb 1;68(3):826-33
18245484
Semin Oncol. 1988 Apr;15(2 Suppl 1):20-5
3285482
Breast Cancer Res Treat. 1992;24(2):85-95
8095168
Cancer Res. 2006 Aug 15;66(16):8266-73
16912207
Bioinformatics. 2004 Nov 22;20(17):3246-8
15180930
Science. 1989 May 12;244(4905):707-12
2470152
Breast Cancer Res. 2004;6(6):240-5
15535853
Lancet. 2005 Feb 19-25;365(9460):671-9
15721472
Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8
9843981
Technol Cancer Res Treat. 2006 Dec;5(6):565-71
17121432
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
11553815
J Natl Cancer Inst. 2004 Jun 16;96(12):926-35
15199112
Oncogene. 2001 Nov 8;20(51):7514-23
11709723
N Engl J Med. 1998 Nov 26;339(22):1609-18
9828250
Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13550-5
16141321
Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23
12829800
J Steroid Biochem Mol Biol. 2005 Feb;93(2-5):249-56
15860267
J Steroid Biochem Mol Biol. 1997 Jun;62(2-3):119-28
9393947
Nature. 2002 Jan 31;415(6871):530-6
11823860
BMC Genomics. 2007 Jul 31;8:258
17663798
J Natl Cancer Inst. 2007 May 2;99(9):694-705
17470737
Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9393-8
15194824
Genome Biol. 2006;7(4):R28
16606439
Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13544-9
16174746
Oncogene. 2007 Jul 12;26(32):4648-55
17213801
Breast Cancer Res Treat. 1994;31(1):117-27
7981452
Cancer Res. 2006 Apr 1;66(7):3903-11
16585219
Cancer Res. 1985 Feb;45(2):584-90
3967234
J Clin Oncol. 2005 Apr 10;23(11):2469-76
15753463
Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):31-6
11134512
N Engl J Med. 2002 Dec 19;347(25):1999-2009
12490681
Cancer. 2005 Jul 15;104(2):257-63
15952182
J Natl Cancer Inst. 2000 Dec 6;92(23):1926-34
11106684
J Natl Cancer Inst. 1995 May 17;87(10):746-50
7563152